Pfizer: One of the world's premier biopharmaceutical companies

Our COVID-19 Vaccine Study – What’s Next?

Our Science

Our COVID-19 Vaccine Study – What’s Next?

Read The Update

COVID-19 SCIENTIFIC RESOURCES

Our Science

COVID-19 SCIENTIFIC RESOURCES

Current information on our scientific progress to bring forward a safe and effective vaccine to help protect against the novel coronavirus.

More Here

COVID-19 CLINICAL TRIAL RESULTS

Our Science

COVID-19 CLINICAL TRIAL RESULTS

Updates on our COVID-19 clinical trial.

Learn More

VISIT OUR COVID-19 HUB

Your Health

VISIT OUR COVID-19 HUB

Sharing resources to stay safe and updates on our efforts we hope could bring an end to the global health crisis.

Learn More

Search products

Search products, A–Z

Need help paying for Pfizer medicines?

Find a Trial

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

THE ANTIGEN: #COVID19 PODCAST

Podcasts

THE ANTIGEN: #COVID19 PODCAST

Season 2 of The Antigen podcast focuses on COVID-19, Pfizer’s response to the crisis and more.

Listen & subscribe here

Cancer Screening: Get it Done

Your Health

Cancer Screening: Get it Done

A new initiative encourages people to speak with their doctor about keeping up with cancer screenings & follow-up appointments, where it’s safe to do so, during the COVID-19 pandemic.

Learn about this new initiative

Latest News

Pfizer Doses First Participant in Phase 3 Study…

– If approved, marstacimab has potential to be a best-in-class treatment option among novel non-factor agents – Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in the Phase 3 BASIS study of marstacimab (PF-06741086), an anti-tissue factor pathway inhibitor (anti-TFPI) being evaluated for the treatment of people with severe hemophilia A or B, with or without inhibitors. BASIS is a global Phase 3, open-label, multicenter study that will evaluate annualized bleed…